Ximelagatran (Exanta): Alternative to Warfarin?(Pharmacology Notes) (Drug Overview)

For decades, the standards of antithrombotic therapy have been heparin and coumarin compounds, primarily warfarin (1). Other newer approaches include low-molecular-weight heparins, fondaparinux, lepirudin, argatroban, and melagatran (investigational). Although existing treatments are effective, they have many limitations. A safer,...

Darbepoetin Alfa (Aranesp) (Pharmacology Notes) (Drug Overview)

The Food and Drug Administration (FDA) approved darbepoetin alfa (Aranesp) for treatment of anemia as sociated with chronic renal failure (CRF) in patients on dialysis and patients not on dialysis (1). The manufacturer of the drug also filed an...

Standing in the Gap: The Primary Care Physician and Alzheimer’s Disease (Scientific Article: Special Issue) (Disease/Disorder Overview)

Introduction An astonishing volume of material has been published about Alzheimer’s disease in recent years. Typing the word “Alzheimer’s” into Google will reward you with 13,600,000 “results” in 0.15 seconds, and a PubMed search of the same instantly yields...

Disclosure of Personal Information (Medicolegal Issues) (Law Overview)

It is well known that personal information, such as health care records, is privileged. As discussed last issue, the federal government has recently taken additional steps to ensure that the privileged nature of this information is maintained. Financial information...

2008 New Drug Approvals (Pharmacology Notes) (Drug Overview)

This article provides a brief review of selected new drug entities approved by the Food and Drug Administration (FDA) in 2008. ALVIMOPAN (ENTEREG)

Hereditary Nonpolyposis Colorectal Cancer in Pakistan: Results of a Pilot Study (Disease/Disorder Overview)

Byline: Mutahir A. Tunio, Mansoor Rafi and Altaf Hashmi – E-mail: [email protected] ABSTRACT

Diagnosis and Treatment of Carotid Body Tumors (Disease/Disorder Overview)

Byline: Halil Basel, Hasan Ozturk, Cemalettin Aydin, Cemil Goya and Ekrem Bayar ABSTRACT

Eszopiclone (Lunesta): A New Nonbenzodiazepine Hypnotic Agent (Pharmacology Notes) (Drug Overview)

Randomized, placebo-controlled trials have shown that eszopiclone, a newly available nonbenzodiazepine hypnotic, effectively treats the symptoms of insomnia. Its pharmacokinetic and pharmacodynamic parameters are similar to those of the other currently available nonbenzodiazepine hypnotics (i.e., zolpidem and zaleplon). The...

Metabolic Syndrome (Medical Condition Overview)

What Is It? Metabolic syndrome is not a disease, but a clustering or “constellation” of health markers related to weight, lack of exercise and genetics.

Atstaff Announces That the Ohio State University Medical Center and Wake Forest University Baptist Medical Center have Selected Clairvia(R) Staff and Demand Management Software Systems (Company Overview)

WORCESTER, MA. Bom, Lilli E. (Pustowka). Funeral services will be private. Died Sunday, March 09, 2008. Funeral Home: Caswell-King Funeral Home, 474 Grove St., Worcester. WORCESTER, MA. DiRocco, Helen P., 84. Arrangements are incomplete. Died Monday, March 10, 2008....

Update on the Medical and Surgical Treatment of Chronic Suppurative Otitis Media Without Cholesteatoma (Disease/Disorder Overview)

A diagnosis of chronic suppurative otitis media (CSOM) without cholesteatoma requires the presence of four conditions: * The otorrhea must emanate from the middle ear via a tympanic membrane perforation or a tympanostomy tube.

Psoriasis, Introduction, General Information, Epidemiology/Psoriasis, Genel Bilgiler, Epidemiyoloji (Continuing Medical Education/Surekli Egitim) (Disease/Disorder Overview)

Giris Psoriasis, keskin sinirli, eritemli plak veya papuller uzerinde yerlesmis parlak, sedefi-beyaz skuamlarla karakterize, kronik seyirli, inflamatuvar bir hastaliktir (1). Skuamlarin renginden dolayi halk arasinda “Sedef Hastaligi” olarak bilinmektedir. Hastalik siklikla sacli deri, diz, dirsek, sakral bolge ve eklemlerin...

Medical Devices: Lost in Regulation (Perspectives) (Company Overview)

The implanted medical device industry was founded in the United States and has been a major economic success and the source of numerous life-saving and life-improving technologies. In the 1950s and 1960s, technological innovations such as the cardiac pacemaker...

Post-Ablative Hypothyroidism (Scientific Article) (Disease/Disorder Overview)

This study was presented at the 17th Annual Meeting of the American Association of Clinical Endocrinologists, Orlando Florida. Introduction

Prostate Cancer: Where Are We?(Disease/Disorder Overview)

In this editorial review, I will provide an overview of prostate cancer. The specific areas I will discuss include the biology of prostate cancer and its prevention; the staging, early detection, and watchful waiting of prostate cancer; and the...

Tiotropium (Spiriva): A Once-Daily Inhaled Anticholinergic Medication for Chronic Obstructive Pulmonary Disease (Pharmacology Notes) (Drug Overview)

Tiotropium represents a new generation of inhaled therapy. No other inhaled product has demonstrated effectiveness with once-daily dosing. Treatment has been associated with improved lung function, decrease in the number of exacerbations, increase in the time to first exacerbation,...

The Emergency Medical Treatment and Active Labor Act (EMTALA): What It Is and What It Means for Physicians (Law Overview)

The Emergency Medical Treatment and Active Labor Act (EMTALA) was passed by the US Congress in 1986 as part of the Consolidated Omnibus Reconciliation Act (COBRA), much of which dealt with Medicare issues. The law’s initial intent was to...

Dengue Fever (Disease/Disorder Overview)

Byline: Rizwan Iqbal – Email [email protected] and M Kashif Munir What is dengue?

Frequency and Pattern of Ovarian Tumours (Disease/Disorder Overview)

Byline: Uzma Bukhari, Qamarunisa Memon and Habibullah Memon ABSTRACT

Expert Reports (Medicolegal Issues) (Law Overview)

In 1996, article 4590i of the Texas Revised Civil Statutes Annotated, the statutory provision that governs health care liability claims in Texas, was amended to require claimants to file expert reports within 180 days as part of the prosecution...